Find information on thousands of medical conditions and prescription drugs.

Bontril

Phendimetrazine (BontrilĀ®) is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule IV drug under the Convention on Psychotropic Substances. In the United States, phendimetrazine is a Schedule III controlled substance under the Uniform Controlled Substances Act of 1970.

To a certain extent phendimetrazine is metabolized into phenmetrazine, which may account for parts of its anorectic effect.

Home
Diseases
Medicines
A
B
Baciim
Bacitracin
Baclofen
Bactrim
Bactroban
Barbexaclone
Barbital
Baros
Basiliximab
Baycol
Beclamide
Beclometasone
Beclovent
Beconase
Beldin
Benadryl
Benazepril
Bendroflumethiazide
Benserazide
Bentiromide
Benylin
Benzaclin
Benzalkonium chloride
Benzocaine
Benzonatate
Betacarotene
Betadine
Betahistine
Betamethasone
Betaxolol
Bextra
Biaxin
Bibrocathol
Bicalutamide
Bicillin
Biclotymol
Biotin
Bisoprolol
Bleomycin
Blocadren
Boldenone
Boniva
Bontril
Bosentan
Bravelle
Brethaire
Brevibloc
Brevicon
Bricanyl
Bromazepam
Bromelain
Bromhexine
Bromocriptine
Brompheniramine
Bronkodyl
Bronopol
BSS
Bucet
Budesonide
Bumetanide
Bupivacaine
Buprenex
Buprenorphine
Buserelin
Buspar
Buspirone
Busulfan
Butalbital
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Obesity
From OB/GYN News, 9/1/04 by Mitchel L. Zoler

Withdrawal of the popular obesity drugs fenfluramine and dexfenfluramine (Redux) from the U.S. market in 1997 left Americans hungry for new obesity drugs with long-term efficacy. They're still waiting, as their waistlines continue to grow.

In other words, there's no weight-loss drug now available that's close to ideal. Obesity plus overweight remains the most common nutritional disorder in the United States, with a prevalence that has ballooned by 75% since 1980. Available pharmacologic agents are rarely effective for weight loss or for improving obesity-related conditions unless they're used as part of a comprehensive approach that also includes dietary and lifestyle changes and behavioral therapy. Patients often regain weight after stopping treatment. But despite these shortcomings, some type of drug therapy is recommended for patients with a body mass index of 27 kg/[m.sup.2] or higher and obesity-related morbidity, and for everyone with a BMI of 30 kg/[m.sup.2] or higher.

Orlistat and sibutramine are the newest obesity drugs and are the only ones approved for long-term use. Both have been studied for at least 2 years. Along with behavioral interventions, these drugs are generally modestly effective for weight loss and maintenance, compared with placebo.

Behavioral interventions--which can be as simple as support group participation or consulting a registered dietitian--enhance the effects of treatment. In one study with 57 patients, loss of at least 15% of body weight was the benchmark for success. This goal was reached by 15% of patients treated with a drug only, 25% of those treated with a drug plus participation in a lifestyle intervention group, and 60% of patients who got the drug and participated in both lifestyle and behavioral intervention groups.

With the exception of orlistat, which is not absorbed into the systemic circulation, obesity drugs should be avoided by women who are pregnant or breast-feeding. A number of experts also don't prescribe orlistat during pregnancy.

Several other drugs are in development. Cannabinoid receptor blockers, now in phase III trials, may become the first approved appetite-reducing drugs that are not stimulants. Topiramate and other antiepileptics are being studied for obesity and may be particularly good for patients with bingeing disorders.

--Mitchel L. Zoler, Editor

--Sharon Worcester, Writer

COPYRIGHT 2004 International Medical News Group
COPYRIGHT 2004 Gale Group

Return to Bontril
Home Contact Resources Exchange Links ebay